Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.
Animals
Anti-Inflammatory Agents
/ pharmacology
Antiviral Agents
/ pharmacology
COVID-19
/ prevention & control
Cell Survival
/ drug effects
Chlorocebus aethiops
Curcumin
/ pharmacology
Cytokines
/ genetics
Healthy Volunteers
Humans
Leukocytes, Mononuclear
/ drug effects
SARS-CoV-2
/ drug effects
Vero Cells
COVID-19 Drug Treatment
COVID-19
D614G strain
Delta variant
SARS-CoV-2
antiviral
curcumin
immune response
inflammation
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
14
10
2021
revised:
05
11
2021
accepted:
11
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Due to the scarcity of therapeutic approaches for COVID-19, we investigated the antiviral and anti-inflammatory properties of curcumin against SARS-CoV-2 using in vitro models. The cytotoxicity of curcumin was evaluated using MTT assay in Vero E6 cells. The antiviral activity of this compound against SARS-CoV-2 was evaluated using four treatment strategies (i. pre-post infection treatment, ii. co-treatment, iii. pre-infection, and iv. post-infection). The D614G strain and Delta variant of SARS-CoV-2 were used, and the viral titer was quantified by plaque assay. The anti-inflammatory effect was evaluated in peripheral blood mononuclear cells (PBMCs) using qPCR and ELISA. By pre-post infection treatment, Curcumin (10 µg/mL) exhibited antiviral effect of 99% and 99.8% against DG614 strain and Delta variant, respectively. Curcumin also inhibited D614G strain by pre-infection and post-infection treatment. In addition, curcumin showed a virucidal effect against D614G strain and Delta variant. Finally, the pro-inflammatory cytokines (IL-1β, IL-6, and IL-8) released by PBMCs triggered by SARS-CoV-2 were decreased after treatment with curcumin. Our results suggest that curcumin affects the SARS-CoV-2 replicative cycle and exhibits virucidal effect with a variant/strain independent antiviral effect and immune-modulatory properties. This is the first study that showed a combined (antiviral/anti-inflammatory) effect of curcumin during SARS-CoV-2 infection. However, additional studies are required to define its use as a treatment for the COVID-19.
Identifiants
pubmed: 34833991
pii: molecules26226900
doi: 10.3390/molecules26226900
pmc: PMC8618354
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antiviral Agents
0
Cytokines
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Universidad de Antioquia
ID : BPIN 2020000100131-SGR
Organisme : Corporación Universitaria Remington
ID : NAT
Organisme : Universidad Cooperativa de Colombia
ID : JCH
Références
Antiviral Res. 2020 Jun;178:104792
pubmed: 32272173
PLoS One. 2013 May 01;8(5):e62482
pubmed: 23658730
J Virol. 2021 Jan 13;95(3):
pubmed: 33173010
Malays J Pathol. 2020 Apr;42(1):3-11
pubmed: 32342926
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
BMC Complement Altern Med. 2019 Nov 6;19(1):298
pubmed: 31694638
Crit Care. 2021 Jul 12;25(1):244
pubmed: 34253247
Sci Rep. 2016 Aug 01;6:30962
pubmed: 27476814
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Vet Microbiol. 2016 Feb 29;184:84-93
pubmed: 26854349
Trends Microbiol. 2017 Jan;25(1):35-48
pubmed: 27743750
Clin Exp Dermatol. 2020 Oct;45(7):902-903
pubmed: 32608046
Physiol Res. 2020 Jul 16;69(3):379-388
pubmed: 32469225
Antiviral Res. 2017 Jun;142:148-157
pubmed: 28343845
Photodiagnosis Photodyn Ther. 2015 Sep;12(3):385-92
pubmed: 26117199
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Front Immunol. 2018 Jun 14;9:1350
pubmed: 29963050
PLoS One. 2013 Sep 18;8(9):e70225
pubmed: 24058438
Drug Des Devel Ther. 2018 Dec 03;12:4095-4105
pubmed: 30584274
PLoS One. 2019 Mar 22;14(3):e0214245
pubmed: 30901375
Int Immunopharmacol. 2020 Dec;89(Pt B):107088
pubmed: 33129099
Evid Based Complement Alternat Med. 2021 Feb 24;2021:6679761
pubmed: 33680061
Nanoscale. 2016 Feb 7;8(5):3040-8
pubmed: 26781043
Sci Rep. 2016 Jun 10;6:27539
pubmed: 27283735
Trends Mol Med. 2020 May;26(5):483-495
pubmed: 32359479
J Surg Res. 2004 Oct;121(2):171-7
pubmed: 15501456
Mol Nutr Food Res. 2015 Nov;59(11):2132-42
pubmed: 26250869
J Agric Food Chem. 2018 Jan 17;66(2):449-456
pubmed: 29224353
Biomedica. 2020 Oct 30;40(Supl. 2):148-158
pubmed: 33152198
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
J Med Chem. 2007 Aug 23;50(17):4087-95
pubmed: 17663539
Future Microbiol. 2020 Dec;15:1747-1758
pubmed: 33404263
Biochem Pharmacol. 1995 Apr 18;49(8):1165-70
pubmed: 7748198
Neuropharmacology. 2015 Dec;99:156-67
pubmed: 26211978
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
J Immunol. 2018 Apr 15;200(8):2835-2846
pubmed: 29549176
Trends Microbiol. 2017 Dec;25(12):968-979
pubmed: 28652073
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514274
Arch Microbiol. 2021 May;203(4):1691-1696
pubmed: 33459817
BMC Complement Altern Med. 2017 Sep 7;17(1):453
pubmed: 28882181
Front Microbiol. 2019 May 03;10:912
pubmed: 31130924
Atherosclerosis. 2014 Jan;232(1):40-51
pubmed: 24401215
Int J Mol Sci. 2019 Oct 02;20(19):
pubmed: 31581661
Nature. 2020 Dec;588(7836):E6
pubmed: 33199918
Pharmacol Res. 2020 Sep;159:104921
pubmed: 32464325
Biomedica. 2021 Oct 15;41(Sp. 2):86-102
pubmed: 34669281
Phytother Res. 2014 May;28(5):633-42
pubmed: 23922235
Mol Nutr Food Res. 2012 May;56(5):691-701
pubmed: 22648616
Sci Rep. 2021 Jan 21;11(1):2043
pubmed: 33479401
Virus Res. 2020 Jul 15;284:197989
pubmed: 32360300
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Biomed Res Int. 2014;2014:186864
pubmed: 24877064
Influenza Other Respir Viruses. 2017 Sep;11(5):457-463
pubmed: 28646616
BMC Complement Altern Med. 2006 Mar 17;6:10
pubmed: 16545122
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS Comput Biol. 2020 Dec 8;16(12):e1008461
pubmed: 33290397
Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
pubmed: 19546349
Virol J. 2011 Dec 28;8:560
pubmed: 22201648
Virusdisease. 2020 Jun;31(2):179-193
pubmed: 32656311
Life Sci. 2020 Jun 15;251:117627
pubmed: 32251634
Immunol Rev. 2015 May;265(1):53-62
pubmed: 25879283
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Front Immunol. 2021 Jul 08;12:708955
pubmed: 34305950
Biomed Pharmacother. 2020 Nov;131:110668
pubmed: 32861965
J Neurosci. 2001 Nov 1;21(21):8370-7
pubmed: 11606625
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900
pubmed: 11712783
Antiviral Res. 2019 Feb;162:71-78
pubmed: 30529358
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nutr Res. 2014 Oct;34(10):886-93
pubmed: 25282128
J Food Drug Anal. 2018 Jul;26(3):1015-1023
pubmed: 29976394